Abstract
OBJECTIVE: To investigate the relationship between childhood mortality (deaths before 18 years of age) and the ethnicity of the child; and how this is related to local measures of deprivation. POPULATION: All child deaths in England, born at, or over, a gestation of 22 weeks, from April 1, 2019, to March 31, 2023, notified to the NCMD DESIGN: Characteristics and death categories were compared by ethnicity, and the rate of death was calculated using a Poisson distribution. Incident Rate Ratios (IRRs) were derived using White children as a baseline, adjusting for deprivation, age, sex, region of England, and area type. MAIN OUTCOME MEASURES: Rate of death between April 2019 and March 2023. RESULTS: Over the 48 months, a total of 12,142 eligible deaths were reported to the NCMD. After adjusting for confounders, children from Asian (IRR 2.37 (2.26-2.49), Black (IRR 3.20 (2.99-3.43)) and Other ethnicities (IRR 1.74 (1.56-1.94), but not Mixed backgrounds (IRR 1.06 (0.98-1.14)), had a higher rate of death than White children. CONCLUSIONS AND RELEVANCE: In England, children from Asian or Asian British, or Black or Black British backgrounds had the highest rate of death before their 18th birthday, and around 1 in 6 deaths in England would be avoided if all children had the rate of death experienced by White children. However, the relationship between ethnicity and the local environment (esp. deprivation and urban status) was profound, and further work is needed to identify how to best target interventions to reduce the overall inequalities seen.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The National Child Mortality Database (NCMD) Programme is commissioned by the Healthcare Quality Improvement Partnership (HQIP) as part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP). HQIP is led by a consortium of the Academy of Medical Royal Colleges, the Royal College of Nursing, and National Voices. Its aim is to promote quality improvement in patient outcomes. HQIP holds the contract to commission, manage and develop the National Clinical Audit and Patient Outcomes Programme (NCAPOP), comprising around 40 projects covering care provided to people with a wide range of medical, surgical and mental health conditions. NCAPOP is funded by NHS England, the Welsh Government and, with some individual projects, other devolved administrations and crown dependencies www.hqip.org.uk/national-programmes. NHS England provided additional funding to the NCMD to enable rapid set up of the real-time surveillance system and staff time to support its function but had no input into the data analysis or interpretation. KL is partly funded by National Institute for Health and Care Research Applied Research Collaboration West (NIHR ARC West)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The NCMD legal basis to collect confidential and personal level data under the Common Law Duty of Confidentiality has been established through the Children Act 2004 Sections M - N, Working Together to Safeguard Children 2018 (https://consult.education.gov.uk/child-protection-safeguarding-and-family-law/working-together-to-safeguard-children-revisions-t/supporting_documents/Working%20Together%20to%20Safeguard%20Children.pdf) and associated Child Death Review Statutory & Operational Guidance https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/859302/child-death-review-statutory-and-operational-guidance-england.pdf). The NCMD legal basis to collect personal data under the General Data Protection Regulation (GDPR) without consent is defined by GDPR Article 6 (e) Public task and 9 (h) Health or social care (with a basis in law). This specific project was reviewed by the Chair of the Central Bristol NHS Research Ethics Committee (Dr Julie Woodley), who has confirmed that it is exempt from NHS permissions or NHS ethical approval.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Aggregate data may be available on request to the corresponding author, and subject to approval by HQIP.
